Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Natural history of multiple myeloma with de novo del(17p)

A. Lakshman, U. Painuly, SV. Rajkumar, RP. Ketterling, P. Kapoor, PT. Greipp, MA. Gertz, FK. Buadi, MQ. Lacy, D. Dingli, A. Dispenzieri, AL. Fonder, SR. Hayman, MA. Hobbs, WI. Gonsalves, YL. Hwa, N. Leung, RS. Go, Y. Lin, TV. Kourelis, R....

. 2019 ; 9 (3) : 32. [pub] 20190307

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, Research Support, N.I.H., Extramural

Perzistentní odkaz   https://www.medvik.cz/link/bmc20006544

Grantová podpora
P50 CA186781 NCI NIH HHS - United States

We compared the outcomes of 310 patients with newly diagnosed multiple myeloma with del(17p) detected by FISH to patients with high-risk translocations (HRT) (n = 79) and standard-risk (SR) cytogenetics (n = 541). The median progression-free survival (PFS) following initial therapy for the three groups was 21.1, 22, and 30.1 months, respectively (P = 0.437- del(17p) vs. HRT); the median overall survival (OS) was 47.3, 79.1, and 109.8 months, respectively, (P = 0.007- del(17p) vs. HRT). PFS and OS for patients with relative loss of 17p (n = 21) were comparable to other patients with del(17p). The PFS was similar between the del(17p) and HRT groups when stratified for age, ISS stage or treatment. The OS of del(17p) and HRT groups were similar in presence of advanced age, ISS III stage or if patients did not receive a proteasome-inhibitor containing induction. ISS III stage, high LDH and HRT, but not the percentage of cells with del(17p) predicted shorter OS in patients with del(17p). The median OS for low (ISS I, normal LDH and no HRT), intermediate (neither low nor high-risk) and high-risk (ISS III and either elevated LDH or coexistent HRT) groups among del(17p) patients were 96.2, 45.4, and 22.8 months, respectively, allowing further risk stratification.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20006544
003      
CZ-PrNML
005      
20200528091743.0
007      
ta
008      
200511s2019 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1038/s41408-019-0191-y $2 doi
035    __
$a (PubMed)30846679
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Lakshman, Arjun $u Division of Hematology, Mayo Clinic, Rochester, MN, USA.
245    10
$a Natural history of multiple myeloma with de novo del(17p) / $c A. Lakshman, U. Painuly, SV. Rajkumar, RP. Ketterling, P. Kapoor, PT. Greipp, MA. Gertz, FK. Buadi, MQ. Lacy, D. Dingli, A. Dispenzieri, AL. Fonder, SR. Hayman, MA. Hobbs, WI. Gonsalves, YL. Hwa, N. Leung, RS. Go, Y. Lin, TV. Kourelis, R. Warsame, JA. Lust, SJ. Russell, SR. Zeldenrust, RA. Kyle, SK. Kumar,
520    9_
$a We compared the outcomes of 310 patients with newly diagnosed multiple myeloma with del(17p) detected by FISH to patients with high-risk translocations (HRT) (n = 79) and standard-risk (SR) cytogenetics (n = 541). The median progression-free survival (PFS) following initial therapy for the three groups was 21.1, 22, and 30.1 months, respectively (P = 0.437- del(17p) vs. HRT); the median overall survival (OS) was 47.3, 79.1, and 109.8 months, respectively, (P = 0.007- del(17p) vs. HRT). PFS and OS for patients with relative loss of 17p (n = 21) were comparable to other patients with del(17p). The PFS was similar between the del(17p) and HRT groups when stratified for age, ISS stage or treatment. The OS of del(17p) and HRT groups were similar in presence of advanced age, ISS III stage or if patients did not receive a proteasome-inhibitor containing induction. ISS III stage, high LDH and HRT, but not the percentage of cells with del(17p) predicted shorter OS in patients with del(17p). The median OS for low (ISS I, normal LDH and no HRT), intermediate (neither low nor high-risk) and high-risk (ISS III and either elevated LDH or coexistent HRT) groups among del(17p) patients were 96.2, 45.4, and 22.8 months, respectively, allowing further risk stratification.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a protokoly protinádorové kombinované chemoterapie $7 D000971
650    _2
$a nádorové biomarkery $7 D014408
650    _2
$a chromozomální aberace $7 D002869
650    12
$a chromozomální delece $7 D002872
650    12
$a lidské chromozomy, pár 17 $7 D002886
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a genetické asociační studie $7 D056726
650    _2
$a genetická predispozice k nemoci $7 D020022
650    _2
$a lidé $7 D006801
650    _2
$a hybridizace in situ fluorescenční $7 D017404
650    _2
$a indukční chemoterapie $7 D060828
650    _2
$a Kaplanův-Meierův odhad $7 D053208
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a mnohočetný myelom $x diagnóza $x genetika $x mortalita $x terapie $7 D009101
650    _2
$a staging nádorů $7 D009367
650    _2
$a plazmatické buňky $x metabolismus $x patologie $7 D010950
650    _2
$a prognóza $7 D011379
655    _2
$a časopisecké články $7 D016428
655    _2
$a Research Support, N.I.H., Extramural $7 D052061
700    1_
$a Painuly, Utkarsh $u 4th Department of Internal Medicine - Hematology, University Hospital Hradec Kralove and Charles University in Prague, Faculty of Medicine in Hradec Kralove, Czech Republic, Hradec Kralove, Czech Republic.
700    1_
$a Rajkumar, S Vincent $u Division of Hematology, Mayo Clinic, Rochester, MN, USA.
700    1_
$a Ketterling, Rhett P $u Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
700    1_
$a Kapoor, Prashant $u Division of Hematology, Mayo Clinic, Rochester, MN, USA.
700    1_
$a Greipp, Patricia T $u Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
700    1_
$a Gertz, Morie A $u Division of Hematology, Mayo Clinic, Rochester, MN, USA.
700    1_
$a Buadi, Francis K $u Division of Hematology, Mayo Clinic, Rochester, MN, USA.
700    1_
$a Lacy, Martha Q $u Division of Hematology, Mayo Clinic, Rochester, MN, USA.
700    1_
$a Dingli, David $u Division of Hematology, Mayo Clinic, Rochester, MN, USA.
700    1_
$a Dispenzieri, Angela $u Division of Hematology, Mayo Clinic, Rochester, MN, USA.
700    1_
$a Fonder, Amie L $u Division of Hematology, Mayo Clinic, Rochester, MN, USA.
700    1_
$a Hayman, Suzanne R $u Division of Hematology, Mayo Clinic, Rochester, MN, USA.
700    1_
$a Hobbs, Miriam A $u Division of Hematology, Mayo Clinic, Rochester, MN, USA.
700    1_
$a Gonsalves, Wilson I $u Division of Hematology, Mayo Clinic, Rochester, MN, USA.
700    1_
$a Hwa, Yi Lisa $u Division of Hematology, Mayo Clinic, Rochester, MN, USA.
700    1_
$a Leung, Nelson $u Division of Hematology, Mayo Clinic, Rochester, MN, USA.
700    1_
$a Go, Ronald S $u Division of Hematology, Mayo Clinic, Rochester, MN, USA.
700    1_
$a Lin, Yi $u Division of Hematology, Mayo Clinic, Rochester, MN, USA.
700    1_
$a Kourelis, Taxiarchis V $u Division of Hematology, Mayo Clinic, Rochester, MN, USA.
700    1_
$a Warsame, Rahma $u Division of Hematology, Mayo Clinic, Rochester, MN, USA.
700    1_
$a Lust, John A $u Division of Hematology, Mayo Clinic, Rochester, MN, USA.
700    1_
$a Russell, Stephen J $u Division of Hematology, Mayo Clinic, Rochester, MN, USA.
700    1_
$a Zeldenrust, Steven R $u Division of Hematology, Mayo Clinic, Rochester, MN, USA.
700    1_
$a Kyle, Robert A $u Division of Hematology, Mayo Clinic, Rochester, MN, USA.
700    1_
$a Kumar, Shaji K $u Division of Hematology, Mayo Clinic, Rochester, MN, USA. kumar.shaji@mayo.edu.
773    0_
$w MED00187996 $t Blood cancer journal $x 2044-5385 $g Roč. 9, č. 3 (2019), s. 32
856    41
$u https://pubmed.ncbi.nlm.nih.gov/30846679 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20200511 $b ABA008
991    __
$a 20200528091740 $b ABA008
999    __
$a ok $b bmc $g 1525402 $s 1096600
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 9 $c 3 $d 32 $e 20190307 $i 2044-5385 $m Blood cancer journal $n Blood Cancer J $x MED00187996
GRA    __
$a P50 CA186781 $p NCI NIH HHS $2 United States
LZP    __
$a Pubmed-20200511

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace